Horst R L, Wovkulich P M, Baggiolini E G, Uskoković M R, Engstrom G W, Napoli J L
Biochemistry. 1984 Aug 14;23(17):3973-9. doi: 10.1021/bi00312a026.
(23S)-1,23,25-Trihydroxyvitamin D3 was isolated from bovine kidney homogenates incubated with 1,25-dihydroxyvitamin D3 by sequential chromatography through one Sephadex LH-20 column and three high-performance liquid chromatography systems. Ultraviolet absorption spectroscopy and mass spectrometry confirmed the structural assignment. One high-performance liquid chromatography system separated the R and S epimers of 1,23,25-trihydroxyvitamin D3 and indicated that the natural product had the S configuration. Plasma pharmacokinetic studies in rats showed that (23S)-1,23,25-trihydroxy[3H]vitamin D3 was rapidly cleared from plasma (t1/2 = 60 min). 1 alpha,25-Dihydroxy[3H]vitamin D3 26,23-lactone appeared concurrently with the disappearance of (23S)-1,23,25-trihydroxy[3H]vitamin D3. Experiments with radioinert compounds showed that 1,25-dihydroxyvitamin D3 and (23S)-1,23,25-trihydroxyvitamin D3 were efficient precursors to 1,25-dihydroxyvitamin D3 26,23-lactone both in intact and in nephrectomized rats. (25S)-1,25,26-Trihydroxyvitamin D3, however, was ineffective at raising plasma 1,25-dihydroxyvitamin D3 26,23-lactone concentrations. These results confirm the presence of extrarenal 1,25-dihydroxyvitamin D3 23(S)-hydroxylase(s) and demonstrate that C-23 hydroxylation of 1,25-dihydroxyvitamin D3 precedes C-26 hydroxylation in the formation of 1,25-dihydroxyvitamin D3 26,23-lactone. (23S)-1,23,25-Trihydroxyvitamin D3 had no intestinal calcium absorptive or bone calcium resorptive activity when dosed to vitamin D deficient rats at levels up to 500 ng. C-23 oxidation, therefore, appears to be a physiologic pathway of 1,25-(OH)2D3 metabolism and a major pathway for the deactivation of pharmacologic levels of 1,25-dihydroxyvitamin D3.
通过依次经一根葡聚糖凝胶LH - 20柱和三个高效液相色谱系统进行色谱分离,从与1,25 - 二羟基维生素D3一起孵育的牛肾匀浆中分离出了(23S)-1,23,25 - 三羟基维生素D3。紫外吸收光谱和质谱确定了其结构归属。一个高效液相色谱系统分离出了1,23,25 - 三羟基维生素D3的R和S差向异构体,并表明天然产物具有S构型。在大鼠体内进行的血浆药代动力学研究表明,(23S)-1,23,25 - 三羟基[3H]维生素D3能迅速从血浆中清除(半衰期 = 60分钟)。1α,25 - 二羟基[3H]维生素D3 26,23 - 内酯与(23S)-1,23,25 - 三羟基[3H]维生素D3的消失同时出现。使用无放射性化合物进行的实验表明,在完整大鼠和肾切除大鼠中,1,25 - 二羟基维生素D3和(23S)-1,23,25 - 三羟基维生素D3都是1,25 - 二羟基维生素D3 26,23 - 内酯的有效前体。然而,(25S)-1,25,26 - 三羟基维生素D3在提高血浆1,25 - 二羟基维生素D3 26,23 - 内酯浓度方面无效。这些结果证实了肾外存在1,25 - 二羟基维生素D3 23(S)-羟化酶,并证明在1,25 - 二羟基维生素D3 26,23 - 内酯的形成过程中,1,25 - 二羟基维生素D3的C - 23羟化先于C - 26羟化。当以高达500 ng的剂量给维生素D缺乏的大鼠给药时(23S)-1,23,25 - 三羟基维生素D没有肠道钙吸收或骨钙吸收活性。因此,C - 23氧化似乎是1,25 - (OH)2D3代谢的一条生理途径,也是使药理水平的1,25 - 二羟基维生素D3失活的主要途径。